Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab + G-CSF in Refractory/Relapsed ALL
NCT00773149Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2006
- Primary completion
- Jan 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in acute lymphoblastic leukemia (ALL), sponsored by Assistance publique - Hôpitaux de Paris. Started Oct 2006; status: completed.
02
Drugs
alemtuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00773149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00773149.